HC Wainwright reiterated their buy rating on shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) in a research report released on Thursday. The brokerage currently has a $5.00 price target on the stock.

Several other analysts have also recently commented on the stock. Rodman & Renshaw began coverage on shares of HTG Molecular Diagnostics in a research note on Monday, August 22nd. They issued a buy rating and a $5.00 price objective for the company. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a sell rating to a hold rating in a research note on Wednesday, July 13th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $5.25.

Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) traded down 5.26% during mid-day trading on Thursday, reaching $3.06. 403,211 shares of the company traded hands. The company’s market capitalization is $21.57 million. The stock’s 50-day moving average is $2.48 and its 200-day moving average is $2.65. HTG Molecular Diagnostics has a 52 week low of $2.03 and a 52 week high of $6.22.

HTG Molecular Diagnostics (NASDAQ:HTGM) last released its earnings results on Tuesday, August 9th. The company reported ($0.98) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by $0.03. On average, equities analysts predict that HTG Molecular Diagnostics will post ($3.58) EPS for the current fiscal year.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

5 Day Chart for NASDAQ:HTGM

Receive News & Stock Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related stocks with our FREE daily email newsletter.